Authors
Latest:
Montefiore Study May Help Establish Patient Criteria for Proton TherapyIn an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.
Latest:
Dr. Gerber on the Future Landscape of Radiation OncologyNaamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.
Latest:
Dr. Djouder on the Role of Liver Regeneration in HCCNabil Djouder, PhD, discusses the role of liver regeneration in hepatocellular carcinoma.
Latest:
Dr Saba on Findings from the CONTINUUM Trial of Sintilimab in Nasopharyngeal CancerNabil F. Saba, MD, FACP, discusses key findings from the phase 3 CONTINUUM trial of sintilimab plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.
Latest:
Managing Adverse Events With TipifarnibRecommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.
Latest:
Dr. Rizk on the Evolution of Surgery in Lung CancerNabil P. Rizk, MD, MS, MPH, discusses the evolving role of surgery in lung cancer.
Latest:
Dr. Abi-Jaoudeh on Combination of Tirapazamine and Transarterial Embolization in HCCNadine Abi-Jaoudeh, MD, associate professor, Department of Radiological Sciences, director, Research of Interventional Radiology in the Department of Radiological Sciences, University of California Irvine School of Medicine, discusses the combination of tirapazamine (SR-4233) and transarterial embolization in hepatocellular carcinoma (HCC).
Latest:
Dr. Barrett on Addressing Cancer DisparitiesNadine J. Barrett, PhD, Duke Cancer Institute, discusses the need to address cancer disparities during the Association of Community Cancer Centers (ACCC) 43rd Annual Meeting.
Latest:
Dr. Tung Discusses the Role of Olaparib in Breast CancerNadine M. Tung, MD, associate professor of medicine, Harvard Medical School, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Center, discusses the role of olaparib (Lynparza) in the treatment of patients with breast cancer.
Latest:
Dr. Arber on Aspirin for Colorectal Cancer PreventionNadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.
Latest:
Advancement in Treating Uncommon EGFR Mutations: Key TakeawaysDiscover the latest insights on treating uncommon EGFR mutations, emphasizing the importance of NGS, personalized therapy, and ongoing advancements in TKIs and ADCs.
Latest:
Nagi Kumar on Green Tea Catechin Treatment for Prostate Cancer PreventionNagi B. Kumar, PhD, Professor/Director, Cancer Chemoprevention, Moffitt Cancer Center, discusses the potential of green tea catechins for the prevention of prostate cancer.
Latest:
Therapeutic Ratio of Hypofractionation in Early Glottic Cancer: A Topic Worth Revisiting?A retrospective experience suggests that early glottic cancer treated with HRT results in a higher incidence of acute toxicity without improved control compared to CRT delivered in an appropriate OTT.
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck CarcinomaThis study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Latest:
Novel Treatment Advances in Differentiated Thyroid CancerAn overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Latest:
Dr. Rizvi on the Implications of the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLCNaiyer A. Rizvi, MD, discusses the clinical implications of the CheckMate-227 trial examining the use of nivolumab plus ipilimumab in the treatment of patients with non–small cell lung cancer.
Latest:
The Era of Interrogating Single Cells in Cancer Biopsy Is NowEven in seemingly uniform cell populations within subcompartments, cell-cell heterogeneity is becoming more evident, far beyond what was previously expected.
Latest:
Biomarker Dilemma Persists With Immunotherapy in Bladder CancerThe quest continues to identify a predictive biomarker of response to more precisely treat patients with checkpoint inhibitors that, while markedly beneficial to some patients, are not without their own costs and associated immune-related adverse effects.
Latest:
Dr. Davis on IMvigor130 Trial in Metastatic Urothelial CancerNancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.
